Posted on 04/23/2020 9:58:54 AM PDT by rxsid
there’s also quite a bit of discouraging news about remdesivir:
here’s some other views on remdesivir by professsional researchers and medical folk the fake stream enemedia will never publish:
the NEJM article that Gilead had published was totally shredded by professional researchers; one researcher’s conclusion was that the data were “unintelligible” ...
basically, the NEJM article was nothing but a means to fluff Gilead’s sinking stock ....
here’s some of the shredding:
from a medical website:
New data on the investigational antiviral drug remdesivir (Gilead) suggest clinical improvement in 36 of 53 patients (68%) hospitalized for severe COVID-19, according to a new study published online April 10 in the New England Journal of Medicine.
But experts are warning that these data come from compassionate use in a wide variety of patients, with no randomization and no control group.
“It is impossible to know the outcome for this relatively small group of patients had they not received remdesivir,” commented Stephen Griffin, PhD, associate professor at the University of Leeds School of Medicine, United Kingdom, who was not involved with the study.
“As the authors point out, a randomized clinical trial is necessary to determine the true effectiveness of this drug,” Griffin added in comments he provided to the Science Media Centre in London. Such trials are underway. The data from this paper are almost uninterpretable. Prof Stephen Evans, London School of Hygiene & Tropical Medicine
“The data from this paper are almost uninterpretable,” said Stephen Evans, MSc, FRCP, professor of pharmacoepidemiology, London School of Hygiene & Tropical Medicine, who provided comments to the Science Media Centre.
Evans notes that the authors describe multiple caveats that limit interpretation of the results, including the small sample size, the relatively short follow-up, missing data, no follow-up on eight patients, and lack of a randomized control group.
Meanwhile, Josh Farkas, MD, who writes the PulmCrit blog, details his criticisms in a piece entitled, “Eleven reasons the NEJM paper on remdesivir reveals nothing.” Beyond the issues the authors list, he points out several more, including cherry picking of patients. “Remdesivir was aggressively sought-after by thousands of patients with COVID-19,” he writes. “Of these patients, 61 ended up receiving the drug. Why did these patients receive medication, out of scores of patients applying to receive it?”
Also, there are no follow-up data for 8 of the 61 patients who received an initial dose of the drug, leaving 53 for the published analysis, continues Farkas, who is an assistant professor of pulmonary and critical care medicine at the University of Vermont in Burlington.
“What happened to these patients? Did they die from anaphylaxis? Did they get well, sign out against medical advice, and go party? This is unknown — but I’m worried that these patients actually didn’t fare so well,” Farkas writes.
Farkas, like Evans and Griffin, concludes that the data are largely unusable. “Until [a randomized controlled trial] is performed, further compassionate use of remdesivir probably isn’t justified,” he writes.
and more:
“Eleven reasons the NEJM paper on remdesivir reveals nothing”
https://emcrit.org/pulmcrit/pulmcrit-eleven-reasons-the-nejm-paper-on-remdesivir-reveals-nothing/
https://twitter.com/hashtag/PrimumNonNocere
commentary on NEJM:
https://twitter.com/NEJM/status/1248697013870493698
“I want to cry looking at this paper”
https://twitter.com/sgdambrauskas/status/1248731936681590785
here’s some comments about the NEJM article from doctors commenting about it on medscape:
“I question the double standards and intent - no controls, only 53 pts (63-8 excluded suspiciously) scattered over 3 CONTINENTS (so management variable to say the least) and 68% improvement in oxygen score (when 50+% expected to improve on their own) - this gets published in NEJM - gets promptly hailed by Gilead CEO and media. GLD stock had lost 10% over the month after initial hype, it’s anyone’s guess what will happen next. All this while the academics are criticizing HCQ ad-nauseam because it showed 97% pts improved in a poorly controlled trial of 1061 pts conducted by one person.
We don’t know if it will be HCQ or Remdisivir or something else, but can we quit double standards and think of sick and dying patients first?
Why even talk about 53 pts when USA alone has half a million?
What is happening here? “
and another:
“The problem is that Gilead failed to include enough patients in the trial. Their methodology completely eludes me. This drug may very well be as good or better than Hydrochloroquine, as it went through all trials and approval in the past for Ebola, though it was not that effective for that virus.
I question if it is politics here, or just blinders-on overlooking it by the FDA, CDC, or Dr. Fauci, that they have shown but a fraction of the interest in Remdesivir than it did in HC.”
Left side says hydroxychloroquine.
Text says chloroquine.
Two different types.
No azithromax/doxycycline.
No zinc
I call boool sheeeitt on this study.
RummyChick, thanks for posting!
https://www.freerepublic.com/focus/news/3838168/posts?page=35#35
“These characteristics with a large protein spike not found on SARS-COV1 unfortunately do give an appearance that this virus possibly could have come from the Wuhan laboratory as this type of mutation seems unlikely to occur naturally.”
The Chinese went off the plantation on this, their trial such as it is, is of “remdesivir” created by a Chinese company. Remdesivir is an orphan drug, it was developed for Ebola. What impact that has on any patent claims worldwide is not something that I can answer, but this is not the Gilead product. Gilead to my understanding has nothing to do with the Chinese effort. So, for those searching for a motive, I wouldn’t be looking at WHO or China.
accidentally published by WHO?
Maybe they want to crash the stock to buy as much as they can before a real test shows it works. (or it just might be totally useless)
Probably.
You did not expect the politicians, Fauci and Brix to be stuck with stocks that are tanking over the failure of this drug
Is it that drug alone?
This happened with that fake HCQ survey at the VA, too, the one where the HCQ recipients were on respirators, and at death’s door already? Funny how this keeps occurring with antiviral medication studies.
p
Remdesivir is backed by Soros and Gates Foundation.
They’ve been doing their best to put down hydroxychloroquine with the press and pushing the data study from the VA which is far from fair. They used scientists with competing interest to do the analysis of the data. One of the authors had grants from Gilead Sciences, the Remdesivir patent holder.
It was not a clinical study as the press pretends, but an unfair data massage.
DEVASTATING! Renowned French Dr. Didier Raoult DESTROYS Liberal Trump-Hating Media on VA Junk Report on Hydroxychloroquine (VIDEO) https://www.thegatewaypundit.com/2020/04/devastating-renowned-french-dr-didier-raoult-destroys-liberal-trump-hating-media-va-junk-report-hydroxychloroquine-video/?utm_source=Twitter&utm_medium=PostSideSharingButtons&utm_campaign=websitesharingbuttons
I ain’ takin’ no stinkin’ vaccine. I WANT Corona Virus. I’ve got Corona Virus Envy. Screw them and all their high falutin’ cures. THe medical industry is now a death machine.
So what are the Chinese covertly trying to buy out from everywhere?
I presume China’s orginal plan isn’t working. Gilead applied for a Chinese patent for remdesivir in 2016 and are still waiting for the patent. Meanwhile, the Chinese made a copycat version. If they unleashed SAR-Cov-2 (COVID19) into the general populace I have to assume they had hoped to generate a windfall with the only PATENTED version of remdesivir.
Gilead had a good two month stock run on their puffery.
Let’s see if anyone trusts them again.
Covid-19 does not develop resistance to building up everyone’s immune system naturally, nor to IV vitamin C, nor to ozone therapy
The Raspy Midget, Fauxchi, is on LIVE, now, at the WH oval office touting the significant Remdesivir/Gilead international trial results.
Saying...this will be the standard of care.
Hmmmm.
Dr. Anthony Fauci says data from remdesivir coronavirus drug trial shows ‘quite good news’
He’s BACK???
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.